Trial Profile
A Randomized, Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate, 0.5% Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Nov 2013
Price :
$35
*
At a glance
- Drugs Loteprednol etabonate (Primary)
- Indications Ocular inflammation; Postoperative pain
- Focus Therapeutic Use
- Sponsors Bausch & Lomb
- 18 Oct 2013 Pooled analysis published in Advances in Therapy.
- 12 Jan 2012 Actual patient number is 407 according to ClinicalTrials.gov.
- 06 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.